21 a. Composition corporelle et type de rhumatisme inflammatoire, IMC, %MG, obésité et traitements adjuvants, vol.21, issue.22, p.23 ,
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Annals of the Rheumatic Diseases, vol.69, issue.11, pp.2002-2010, 2010. ,
DOI : 10.1136/ard.2009.124446
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis & Rheumatism, vol.64, issue.5, pp.22-32, 2010. ,
DOI : 10.7326/0003-4819-148-2-200801150-00192
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.64, issue.2, 2005. ,
DOI : 10.1136/ard.2004.025130
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Research & Therapy, vol.13, issue.3, p.94, 2011. ,
DOI : 10.1136/ard.2008.089979
Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions, Clin Exp Rheumatol, vol.23, issue.4, pp.469-74, 2005. ,
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.70, issue.7, pp.1208-1223, 2011. ,
DOI : 10.1136/ard.2011.153023
Predictors of response to anti-TNF-?? therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Rheumatology, vol.45, issue.12, pp.1558-65, 2006. ,
DOI : 10.1093/rheumatology/kel149
Analysis of Trial Data for Infliximab and Golimumab: Baseline C-Reactive Protein Level and Prediction of Therapeutic Response in Patients With Psoriatic Arthritis, Arthritis Care & Research, vol.40, issue.7, pp.1114-1122 ,
DOI : 10.1016/j.semarthrit.2010.07.004
C-Reactive Protein as a Marker for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.5, pp.661-666, 2004. ,
DOI : 10.1097/00054725-200409000-00026
Baseline predictors of response to TNF-?? blocking therapy in ankylosing spondylitis, Current Opinion in Rheumatology, vol.24, issue.3, 2012. ,
DOI : 10.1097/BOR.0b013e32835257c5
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study, Arthritis Research & Therapy, vol.13, issue.3, p.82, 2011. ,
DOI : 10.1136/ard.2004.030452
URL : https://hal.archives-ouvertes.fr/hal-00922332
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis, British Journal of Clinical Pharmacology, vol.33, issue.4, pp.55-65 ,
DOI : 10.1007/s10928-006-9012-6
Conventional DMARDs in axial spondyloarthritis: wishful??rather than rational?thinking! Ann Rheum Dis, pp.951-954, 2015. ,
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study, Arthritis Rheum Feb, vol.1559, issue.2, pp.234-274, 2008. ,
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, vol.46, issue.6, pp.1451-1460, 2002. ,
Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review, Acta Dermato Venereologica, vol.95, issue.4, pp.401-407 ,
DOI : 10.2340/00015555-1980
URL : https://hal.archives-ouvertes.fr/hal-01190167
Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, The Journal of Dermatology, vol.15, issue.1, 2013. ,
DOI : 10.1002/ibd.20899
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3791, 2006. ,
DOI : 10.1002/art.22214
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Research & Therapy, vol.13, issue.3, p.105, 2011. ,
DOI : 10.3109/03009740903177745
URL : https://hal.archives-ouvertes.fr/hal-00922822
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, Arthritis Research & Therapy, vol.15, issue.4, p.79, 2013. ,
DOI : 10.1136/ard.2009.124446
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.79, issue.1, pp.118-146 ,
DOI : 10.1016/j.jbspin.2011.11.004
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168386
A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy, Modern Rheumatology, vol.73, issue.2, pp.83-91, 2007. ,
DOI : 10.1016/j.jbspin.2006.01.007
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.26, issue.suppl 28, pp.681-95, 2008. ,
DOI : 10.1592/phco.26.6.813
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis & Rheumatism, vol.6, issue.9, pp.1552-63, 1998. ,
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice, Rheumatology, vol.55, issue.2, pp.210-230 ,
DOI : 10.1093/rheumatology/kev277
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-54, 2006. ,
DOI : 10.1016/j.cgh.2006.06.025
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-711, 2005. ,
DOI : 10.1136/ard.2004.030452
Obesity and reduction of the response rate to anti-tumor necrosis factor ?? in rheumatoid arthritis: An approach to a personalized medicine, Arthritis Care & Research, vol.70, issue.Suppl, pp.94-100, 2013. ,
DOI : 10.1136/ard.2010.135376
Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.72, issue.(1), pp.2029-2062, 2014. ,
DOI : 10.1136/annrheumdis-2012-202254
Body mass index and clinical response to infliximab in rheumatoid arthritis, Arthritis & Rheumatism, vol.54, issue.Suppl 3, pp.359-64, 2011. ,
DOI : 10.1002/art.21671
Body weight, gender and response to TNF-?? blockers in axial spondyloarthritis, Rheumatology, vol.53, issue.5, pp.875-81, 2014. ,
DOI : 10.1093/rheumatology/ket433
URL : http://doi.org/10.1093/rheumatology/ket433
Body mass index influences the response to infliximab in ankylosing spondylitis, Arthritis Research & Therapy, vol.14, issue.3, p.115, 2012. ,
DOI : 10.1093/bja/aeq195
URL : https://hal.archives-ouvertes.fr/inserm-00704843
Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome, The Journal of Rheumatology, vol.43, issue.2, 2016. ,
DOI : 10.3899/jrheum.150648
Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis, Arthritis Care & Research, vol.295, issue.Suppl 2, pp.141-148, 2013. ,
DOI : 10.1001/jama.295.19.2275
The influence of obesity on response to tumour necrosis factor-?? inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries, Rheumatology, vol.55, issue.12, pp.2191-2200, 2016. ,
DOI : 10.1093/rheumatology/kew326
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.10, pp.2118-2142, 2013. ,
DOI : 10.1097/MIB.0b013e31829cf401
Obesity, inflammation, and atherosclerosis, Nature Reviews Cardiology, vol.107, issue.6, 2009. ,
DOI : 10.1161/01.CIR.103.16.2096
Obesity is associated with macrophage accumulation in adipose tissue, Journal of Clinical Investigation, vol.112, issue.12, pp.1796-808, 2003. ,
DOI : 10.1172/JCI19246DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296995
The correlation between adiposity and adiponectin, tumor necrosis factor ??, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?, Journal of Endocrinological Investigation, vol.43, issue.3, pp.210-214, 2007. ,
DOI : 10.1016/j.jacc.2003.11.039
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance., Journal of Clinical Investigation, vol.95, issue.5, pp.2409-2424, 1995. ,
DOI : 10.1172/JCI117936
Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels, European Journal of Gastroenterology & Hepatology, vol.28, issue.3, pp.271-277, 2016. ,
DOI : 10.1097/MEG.0000000000000544
Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis, Clin Exp Rheumatol. Feb, vol.35, issue.1, pp.145-153, 2017. ,
Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality, European Heart Journal, vol.31, issue.6, pp.737-783, 2010. ,
DOI : 10.1093/eurheartj/ehp487
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838679
Relationship between obesity, insulin resistance, and coronary heart disease risk, Journal of the American College of Cardiology, vol.40, issue.5, pp.937-980, 2002. ,
DOI : 10.1016/S0735-1097(02)02051-X
URL : http://doi.org/10.1016/s0735-1097(02)02051-x
Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis, International Journal of Obesity, vol.85, issue.5, pp.791-800, 2010. ,
DOI : 10.1016/S0140-6736(07)61778-4
Accuracy of body mass index in diagnosing obesity in the adult general population, International Journal of Obesity, vol.9, issue.6, pp.959-66, 2008. ,
DOI : 10.1067/mhj.2001.119420
Relationships Between the Body Mass Index and Body Composition, Obesity Research, vol.60, issue.6, pp.35-44, 1996. ,
DOI : 10.1080/07315724.1992.10718272
The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care, Current Rheumatology Reports, vol.25, issue.3, p.6, 2016. ,
DOI : 10.1097/EDE.0000000000000075
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809046
Rheumatoid cachexia: a clinical perspective, Rheumatology, vol.47, issue.8, pp.1124-1155, 2008. ,
DOI : 10.1093/rheumatology/ken146
URL : http://doi.org/10.1093/rheumatology/ken146
Effect of Body Composition Methodology on Heritability Estimation of Body Fatness, The Open Nutrition Journal, vol.6, issue.1, pp.48-58, 2012. ,
DOI : 10.2174/1874288201206010048
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?, Annals of the Rheumatic Diseases, vol.37, issue.(Suppl 11), pp.1132-1139, 2015. ,
DOI : 10.3899/jrheum.091333
Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS) Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score Arthritis Care Res, Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S), pp.47-58, 2011. ,
Use of Body Fatness Cutoff Points, Mayo Clinic Proceedings, vol.85, issue.11, p.1057, 2010. ,
DOI : 10.4065/mcp.2010.0583
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966372
Use of Body Fatness Cutoff Points???Reply???I, Mayo Clinic Proceedings, vol.85, issue.11, pp.1057-1065, 2010. ,
DOI : 10.4065/mcp.2010.0624
More on Body Fat Cutoff Points, Mayo Clinic Proceedings, vol.86, issue.6, 2011. ,
DOI : 10.4065/mcp.2011.0097
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104919
More on Body Fat Cutoff Points???Reply???I, Mayo Clinic Proceedings, vol.86, issue.6 ,
DOI : 10.4065/mcp.2011.0156
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104920
Body composition interpretation, Nutrition, vol.19, issue.7-8, pp.7-8597, 2003. ,
DOI : 10.1016/S0899-9007(03)00061-3
Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98, Int J Obes Relat Metab Disord, vol.26, issue.7, pp.953-60, 2002. ,
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1256, 2007. ,
DOI : 10.1136/ard.2007.072397
Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, vol.20, issue.1, pp.645-60, 2007. ,
DOI : 10.3748/wjg.v11.i8.1187
Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?, Clinical Rheumatology, vol.84, issue.Suppl 10, pp.629-663, 2015. ,
DOI : 10.1016/j.yexmp.2008.03.003
Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab, Annals of the Rheumatic Diseases, vol.71, issue.12, pp.1955-60, 2012. ,
DOI : 10.1136/annrheumdis-2011-200828
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients, Therapeutic Drug Monitoring, vol.PAP, 2008. ,
DOI : 10.1097/FTD.0b013e318180e300
URL : https://hal.archives-ouvertes.fr/hal-00616549
The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am, pp.545-68, 2015. ,
Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study, Clinical Rheumatology, vol.5, issue.12, 2016. ,
DOI : 10.1371/journal.pone.0014328
Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient, J Rheumatol. 2015, vol.42, issue.4, pp.580-584 ,
Body mass index and response to abatacept in rheumatoid arthritis, European Journal of Clinical Investigation, vol.14, issue.Suppl 2, pp.1048-52, 2016. ,
DOI : 10.1186/ar3900
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the ???pan-European registry collaboration for abatacept (PANABA), Clinical Rheumatology, vol.73, issue.S3, 2016. ,
DOI : 10.1136/annrheumdis-2013-204573
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study, Joint Bone Spine, 2016. ,
DOI : 10.1016/j.jbspin.2016.10.011
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology, vol.50, issue.8, pp.1445-52, 2011. ,
DOI : 10.1093/rheumatology/ker124
The speed of change: towards a discontinuity theory of immunity?, Nature Reviews Immunology, vol.4, issue.10, pp.764-773, 2013. ,
DOI : 10.1126/scisignal.2001608
URL : https://hal.archives-ouvertes.fr/hal-01343694
Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis Patients, Arthritis Care & Research, vol.13, issue.8, pp.1235-1277, 2013. ,
DOI : 10.1111/j.1467-789X.2011.00970.x
Increased visceral fat and decreased energy expenditure during the menopausal transition, International Journal of Obesity, vol.6, issue.6, pp.949-58, 2005. ,
DOI : 10.2337/diacare.23.6.801
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748330
Body mass index as a measure of body fatness: age- and sex-specific prediction formulas, British Journal of Nutrition, vol.46, issue.02, pp.105-119, 1991. ,
DOI : 10.1079/BJN19780152
Body mass index and percent body fat: a meta analysis among different ethnic groups, International Journal of Obesity, vol.22, issue.12, 1998. ,
DOI : 10.1038/sj.ijo.0800741
Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship, Obesity Reviews, vol.53, issue.3, pp.141-147, 2002. ,
DOI : 10.1038/sj.ijo.0801353
Sex-specific Associations of Magnetic Resonance Imaging-derived Intra-abdominal and Subcutaneous Fat Areas with Conventional Anthropometric Indices: The Atherosclerosis Risk in Communities Study, American Journal of Epidemiology, vol.144, issue.4, pp.335-380, 1996. ,
DOI : 10.1093/oxfordjournals.aje.a008934
Sex differences in the relation of body composition to markers of inflammation, Atherosclerosis, vol.184, issue.1, 2006. ,
DOI : 10.1016/j.atherosclerosis.2005.04.011
The Use of Anthropometric and Dual-Energy X-ray Absorptiometry (DXA) Measures to Estimate Total Abdominal and Abdominal Visceral Fat in Men and Women, Obesity Research, vol.45, issue.3, pp.256-64, 1999. ,
DOI : 10.2337/diab.45.5.633
Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins : The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study, Circulation, vol.100, issue.7, pp.717-739, 1999. ,
DOI : 10.1161/01.CIR.100.7.717
Effects of hormone therapyon C-reactive protein and IL-6 in postmenopausal women: a review article, Climacteric, vol.85, issue.4, pp.317-343, 2005. ,
DOI : 10.1161/01.CIR.0000028463.74880.EA
The relation of body fat mass and distribution to markers of chronic inflammation, International Journal of Obesity, vol.25, issue.10, pp.1407-1422, 2001. ,
DOI : 10.1038/sj.ijo.0801792
Composition corporelle. Cah Nutr Diététique, pp.172-178, 2005. ,
DOI : 10.1016/s0007-9960(05)80484-5
Fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20???80 year-old Italian population, Clinical Nutrition, vol.27, issue.1, pp.87-94, 2008. ,
DOI : 10.1016/j.clnu.2007.10.008
an observational-monocentric and cross-sectional study, we included consecutive patients treated by IFX for 2 months and more. We collected BMI and %BF from dual-energy X-ray absorptiometry. Serum samples were collected for assay of TSI and anti-IFX antibody (TSI) ,